Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Agilon Health, Inc.

AGLNYSE
Healthcare
Medical - Care Facilities
$0.39
$0.00(0.00%)
U.S. Market opens in 3h 24m

Agilon Health, Inc. Fundamental Analysis

Agilon Health, Inc. (AGL) shows weak financial fundamentals with a PE ratio of -0.69, profit margin of -5.24%, and ROE of -73.12%. The company generates $5.9B in annual revenue with weak year-over-year growth of -2.11%.

Key Strengths

Cash Position147.52%
PEG Ratio-0.27

Areas of Concern

ROE-73.12%
Operating Margin-6.34%
We analyze AGL's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -55.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-55.3/100

We analyze AGL's fundamental strength across five key dimensions:

Efficiency Score

Weak

AGL struggles to generate sufficient returns from assets.

ROA > 10%
-19.31%

Valuation Score

Excellent

AGL trades at attractive valuation levels.

PE < 25
-0.69
PEG Ratio < 2
-0.27

Growth Score

Weak

AGL faces weak or negative growth trends.

Revenue Growth > 5%
-2.11%
EPS Growth > 10%
-55.56%

Financial Health Score

Excellent

AGL maintains a strong and stable balance sheet.

Debt/Equity < 1
0.12
Current Ratio > 1
1.08

Profitability Score

Weak

AGL struggles to sustain strong margins.

ROE > 15%
-7312.37%
Net Margin ≥ 15%
-5.24%
Positive Free Cash Flow
No

Key Financial Metrics

Is AGL Expensive or Cheap?

P/E Ratio

AGL trades at -0.69 times earnings. This suggests potential undervaluation.

-0.69

PEG Ratio

When adjusting for growth, AGL's PEG of -0.27 indicates potential undervaluation.

-0.27

Price to Book

The market values Agilon Health, Inc. at 0.70 times its book value. This may indicate undervaluation.

0.70

EV/EBITDA

Enterprise value stands at -1.21 times EBITDA. This is generally considered low.

-1.21

How Well Does AGL Make Money?

Net Profit Margin

For every $100 in sales, Agilon Health, Inc. keeps $-5.24 as profit after all expenses.

-5.24%

Operating Margin

Core operations generate -6.34 in profit for every $100 in revenue, before interest and taxes.

-6.34%

ROE

Management delivers $-73.12 in profit for every $100 of shareholder equity.

-73.12%

ROA

Agilon Health, Inc. generates $-19.31 in profit for every $100 in assets, demonstrating efficient asset deployment.

-19.31%

Following the Money - Real Cash Generation

Operating Cash Flow

Agilon Health, Inc. generates limited operating cash flow of $-68.83M, signaling weaker underlying cash strength.

$-68.83M

Free Cash Flow

Agilon Health, Inc. generates weak or negative free cash flow of $-98.57M, restricting financial flexibility.

$-98.57M

FCF Per Share

Each share generates $-0.24 in free cash annually.

$-0.24

FCF Yield

AGL converts -46.00% of its market value into free cash.

-46.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.69

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.27

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.70

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.04

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.12

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.08

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.73

vs 25 benchmark

ROA

Return on assets percentage

-0.19

vs 25 benchmark

ROCE

Return on capital employed

-1.05

vs 25 benchmark

How AGL Stacks Against Its Sector Peers

MetricAGL ValueSector AveragePerformance
P/E Ratio-0.6929.45 Better (Cheaper)
ROE-73.12%779.00% Weak
Net Margin-5.24%-24936.00% (disorted) Weak
Debt/Equity0.120.26 Strong (Low Leverage)
Current Ratio1.084.65 Neutral
ROA-19.31%-19344.00% (disorted) Weak

AGL outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Agilon Health, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

352.67%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-505.82%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-84.80%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ